National Institute of Allergy and Infectious Diseases (NIAID)
The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.
Inclusion Criteria: 1. Formerly participated in HVTN 706 study as active vaccine arm or placebo recipient (those enrolled in the active vaccine arm of HVTN 706 must have received all 4 vaccinations according to the HVTN 706 protocol). 2. Demonstrates an understanding of the study and is able and willing to complete the informed consent process. 3. 18 to ≤ 60 years old, on day of enrollment. 4. Available for clinic follow-up through the last clinic visit, willing to undergo FNA, and willing to be contacted 12 months after the last study-product administration. 5. Agrees not to enroll in anothe…
To be administered subcutaneously as 1 mg admixed with Hiltonol, Poly-ICLC as a single dose.
Vaccine adjuvant